Premium
Intracavitary administration of OK‐432 with subcutaneous priming for malignant ascites in a case of advanced renal cell carcinoma
Author(s) -
KAGEYAMA YUKIO,
SAKAI YASUYUKI,
ARAI GAKU,
HYOCHI NOBUHIKO,
SUZUKI MASAHITO,
MASUDA HITOSHI,
KAWAKAMI SATORU,
HAYASHI TETSUO,
OKUNO TETSUO,
KOBAYASHI TSUYOSHI,
KIHARA KAZUNORI
Publication year - 2002
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1046/j.1442-2042.2002.00411.x
Subject(s) - medicine , ascites , renal cell carcinoma , effusion , subcutaneous injection , priming (agriculture) , carcinoma , urology , malignant pleural effusion , pleural effusion , surgery , botany , germination , biology
The intracavitary injection of OK‐432 (a streptococcal preparation) with subcutaneous priming has been shown to be an effective immunotherapy for patients with malignant effusion. We applied this treatment in a case of advanced renal cell carcinoma with massive ascites. The patient received 0.2 Klinishe Einheit (KE) OK‐432 in the subcutaneous injection twice (day 1 and day 7) followed by 10KE OK‐432 intra‐abdominal administration (day 9). The treatment was performed safely without major side‐effects except for transient pyrexia. A significant reduction of ascites was noted 1 month after the treatment without subsequent re‐accumulation. Intracavitary injection of OK‐432 with subcutaneous priming seems to be a simple, safe and effective treatment for ascites in advanced renal cell carcinoma.